Shiven B. Patel,
MD, MBA, FACP
Languages Spoken: English
Shiven B. Patel, MD, MBA, FACP, is an Assistant Professor in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine, and an Investigator at the Huntsman Cancer Institute. Dr. Patel is a specialist in adult hematology and medical oncology, and his main areas of interest include thoracic (head & neck, thyroid, lung, mesothelioma and thymic cancers).
Dr. Patel earned his bachelor’s and medical degrees from The University of Florida in Gainesville, Florida. He then went on to complete an Internal Medicine residency at the University of Maryland School Of Medicine in Baltimore, Maryland. Next he served as an attending physician in Hospitalist Medicine at MedStar Franklin Square in Rosedale, Maryland. Dr. Patel then completed a combined fellowship in hematology and oncology at the University of Utah and the Huntsman Cancer Institute. He served as the Chief Fellow his final year of training and sat on the Graduate Medical Education committee at the University of Utah. Most recently, he completed the MBA program at Indiana University, Kelley School of Business in Indianapolis, Indiana, as well as the Lean Six Sigma Green Belt Certification, through Professional Education at the University of Utah in Salt Lake City.
Dr. Patel is board certified in internal medicine, hematology, and oncology. He is a member of several national organizations such as the American Society of Clinical Oncology, American Society of Hematology and American Association of Cancer Research.
Throughout his medical training, Dr. Patel has been involved in both laboratory and clinical research. He has presented his work at multiple national meetings and published these findings in peer-review articles. He is a co-investigator in a number of clinical trials at the Huntsman Cancer Institute and is working to bring more studies of all phases to benefit his patients to the Huntsman Cancer Institute.
Clinical Locations
Clinic 1A, Thoracic
801-587-4470
Veterans Administration Medical Center
801-582-1565
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
5.0/ 5
Care provider's explanation of condition/problem
5.0/ 5
Care provider's effort to include me in decisions
5.0/ 5
Wait time at clinic
4.4/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
June 10, 2021
HUNTSMAN CANCER CENTER
Dr. Patel is always kind and thorough! I respect his thoughts and expertise. I appreciate him listening to me and give me the advice in clear and precise words. I respect and appreciate Dr. Patel and I am grateful he is my Dr.
UofU Patient
June 03, 2021
HUNTSMAN CANCER CENTER
Dr. Patel is fantastic. He saved my life
UofU Patient
March 24, 2021
HUNTSMAN CANCER CENTER
Dr. Patel addressed all [NAME REMOVED] and my concerns. We both felt good about the upcoming treatments and had a lot better understanding of how treatments will proceed.
UofU Patient
March 06, 2021
HUNTSMAN CANCER CENTER
The doctors assistant was very helpful with my mothers questions, and explained everything in detail with her, she did not leave until my mother was comfortable with all her questions. She was amazing. I was there with my mother the whole time. I really felt comfortable with how she was with my mother.
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
I recommend others to huntsman
UofU Patient
July 12, 2020
HUNTSMAN CANCER CENTER
Excellent rappor with health care team. Team were very in depth in questions asked concerning my current health conditions and deciding what concerns needed addressed or modified. I felt inculded on all decisions on treatment and what direction needed to be taken with future care. I was asked frequently my opinion on all parts of treatment and future decisions on care.
UofU Patient
June 26, 2020
HUNTSMAN CANCER CENTER
Dr is always open and direct with answers. He listens to my concerns and he helps in all aspects. I have pest and confidence in Dr. Patel.
UofU Patient
June 05, 2020
HUNTSMAN CANCER CENTER
Dr. Patel and his team are always willing to answer any questions I or my family have. I believe I was extremely lucky to have Dr Patel and his team to treat me.
UofU Patient
May 03, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
April 15, 2020
HUNTSMAN CANCER CENTER
I have full confidence in Dr. S. Patel and his staff. I as well as my family trust him in his decisions making.
UofU Patient
February 09, 2020
HUNTSMAN CANCER CENTER
Clear, concise explanation of treatment. Addressed my concerns and developed plan for addressing issues in a timely, reasonable treatment. Dr. Patel is excellent and providing what ever it takes to stay ahead of problems and addressing issues as they present their selves.
UofU Patient
January 30, 2020
HUNTSMAN CANCER CENTER
Able to connect and discuss my health care fully. All staff provided full attention and concern over my health issues. Several aspects of prior and optiopns of future treatments were didcussed.
UofU Patient
November 08, 2019
HUNTSMAN CANCER CENTER
My husband and son accompanied me on my appointment. We were all anxious and nervous about what we would learn. Everyone was good about answering all our questions.
Shiven B. Patel, MD, MBA, FACP, is an Assistant Professor in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine, and an Investigator at the Huntsman Cancer Institute. Dr. Patel is a specialist in adult hematology and medical oncology, and his main areas of interest include thoracic (head & neck, thyroid, lung, mesothelioma and thymic cancers).
Dr. Patel earned his bachelor’s and medical degrees from The University of Florida in Gainesville, Florida. He then went on to complete an Internal Medicine residency at the University of Maryland School Of Medicine in Baltimore, Maryland. Next he served as an attending physician in Hospitalist Medicine at MedStar Franklin Square in Rosedale, Maryland. Dr. Patel then completed a combined fellowship in hematology and oncology at the University of Utah and the Huntsman Cancer Institute. He served as the Chief Fellow his final year of training and sat on the Graduate Medical Education committee at the University of Utah. Most recently, he completed the MBA program at Indiana University, Kelley School of Business in Indianapolis, Indiana, as well as the Lean Six Sigma Green Belt Certification, through Professional Education at the University of Utah in Salt Lake City.
Dr. Patel is board certified in internal medicine, hematology, and oncology. He is a member of several national organizations such as the American Society of Clinical Oncology, American Society of Hematology and American Association of Cancer Research.
Throughout his medical training, Dr. Patel has been involved in both laboratory and clinical research. He has presented his work at multiple national meetings and published these findings in peer-review articles. He is a co-investigator in a number of clinical trials at the Huntsman Cancer Institute and is working to bring more studies of all phases to benefit his patients to the Huntsman Cancer Institute.
Academic Locations
Huntsman Cancer Hospital
801-213-5658
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Research Interests
- Lung Cancer
- Hematology
- Mesothelioma
- Thymoma
- Thoracic Oncology
Education History
| Graduate Training | Indiana University, Kelley School of Business Business of Medicine M.B.A. |
| Fellowship | Huntsman Cancer Institute and Veterans Affairs Hospital Hematology and Oncology Chief Fellow |
| Fellowship | Huntsman Cancer Institute and Veterans Affairs Hospital Hematology and Oncology Fellow |
| Residency | University of Maryland Medical System and Baltimore VA Medical Center Internal Medicine Resident |
| Internship | University of Maryland Medical System and Baltimore VA Medical Center Internal Medicine Intern |
| Professional Medical | University of Florida College of Medicine Medicine M.D. |
| Undergraduate | University of Florida College of Liberal Arts and Sciences Major: Basic Biology & Medicine; Minor: Business Administration B.S. |
| Undergraduate | University of Florida, College of Liberal Arts and Sciences Honors Program A.A. |
| Certification | University of Utah Lean Six Sigma Green Belt, Professional Education Certification |
Selected Publications - Journal Articles
Journal Article
- Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 1078155220924719.
- Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 1-4.
- Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, JOP1900329.
- Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA (2020). NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw, 18(1), 12-22.
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. (Epub ahead of print) Target Oncol.
- Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 1078155219835912.
- Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. J Radiat Oncol, 7(3), 223-232.
- Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal Sumanta K, Stenehjem DD, Agarwal N (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 3, 190-197.
- Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017). Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(12), 1520-1541.
- Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi S, Gastier-Foster JM, Schiffman JD, Miles RR (2017). Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leuk Res, 56, 44-51.
- Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high does interleukin-2 in patients with renal cell carcinoma. BMC Urology.
- Agarwal N, Alex AB, Farnham JM, Patel SB, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). J Urol.
- Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
- Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
- Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
- Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer, 45 Suppl 1, 278-81.
- Julian D, April KL, Patel S, Stein JR, Wohlgemuth SE (2005). Mitochondrial depolarization following hydrogen sulfide exposure in erythrocytes from a sulfide-tolerant marine invertebrate. J Exp Biol, 208(Pt 21), 4109-22.
Review
Case Report
Editorial
- Patel SB, Tuan J (2021). A Community Perspective: Latest 340B Program’s Effect on Cancer Centers. https://dailynews.ascopubs.org/do/10.1200/ADN.21.200434/full/.
Letter
Abstract
- Kerrigan K, Chipman J, Jo YJ, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel S (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy [Abstract]. 16(3), S57-S698.
- Kerrigan K, Puri S, Sinnott J, Haaland B, Akerley W, Patel S (2021). Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis [Abstract]. 16(3), S690.
- Puri S, Patel S, Chalmers A, Kerrigan K, Loertscher E, George S, Boucher K, Akerley W (2021). Phase 1b Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCL [Abstract]. 16(3), S344.
- Fitzgerald L, Sinnott J, Trunk A, Chalmers A, Akerley W, Patel S (2021). Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6 [Abstract]. 16(3), S238-S239.
- Neal J, Lim F, Felip E, Gentzler R, Patel S, Baranda J, Fang B, Squillante C, Simonelli M, Werneke S, Curran D, Aix SP (2021). Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021 [Abstract]. 16(3), S230-S231.
- Kerrigan K, Chipman J, Jo YJ, Haaland B, Johnson E, Puri S, Varghese T, Akerley W, Patel S (2021). Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. 2020 World Conference on Lung Cancer. [Abstract]. 16(3), S122-S123.
- Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. doi: https://doi.org/10.1016/j.cllc.2021.01.013 [Abstract].
- Neal JW, Lim FL, Felip E, Gentzler RD, Patel SB, Baranda J, Fang B, Squillante CM, Simonelli M, Werneke S, Curran D, Aix SP (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. (suppl) abstr 9610 [Abstract]. 38.
- Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.doi:10.1002/cam4.2625 [Abstract].
- Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), S369-S370.
- Lim F, Ponce S, Patel S, Van Herpen C, Kurkjian C, Lou Y, Liu Y, Ramsingh G, Pal S, Neal J (2019). P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [Abstract]. 14(10), S405-S406.
- Kerrigan, K, Haaland B, Adamson B, Patel S, Akerley W (2019). MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-S308.
- Moser J, Wei G, Colonna S, Grossmann KF, Patel S, Hyngstrom J (2019). Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma [Abstract]. 30.
- Johnson ED, Kerrigan K, Bulter K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy [Abstract]. Journal of Oncology Pharmacy Practice.
- Coman G, Moser J, Hyngstrom J, Grossmann K, Patel SB, Colonna S, Andtbacka R (2018). Overall Survival of Patients Treated with Single Agent Ipilimumab or Combination Nivolumab and Ipilimumab in Second Line Setting After Progression on Frontline Anti-PD-1 Therapy [Abstract].
- Chalmers A, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W (2018). P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) [Abstract]. Journal of Thoracic Oncology, 13(10), S872.
- Patel SB, Akerley WL, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Meropol NJ, Haaland B (2018). Prognostic value of patient-reported outcomes (PROs) in advanced cancer [Abstract]. Journal of Clinical Oncology, 36.
- McPherson JP, Patel SB, Igumnova E, Pettit J, Ose D, Haydell T, Martineau J, Meropol NJ, Beck AC (2018). Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL) [Abstract]. Journal of Clinical Oncology, 36.
- Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Kissell B, Meropol NJ, Akerley WL (2018). Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer (abstr 10101) [Abstract]. Journal of Clinical Oncology, 36(15).
- Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy [Abstract]. (7), 223–232.
- Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel S, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 35(6S suppl), abstract 265.
- Thibault J, Patel SB (2017). A Case of Mytomycin-C Induced Pulmonary Veno-Occlusive Disease [Abstract]. AVAHO Updates.
- Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5066.
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5083.
- Kuzman JA, Stenehjem DD, Patel SB, Merriman J, Gill DM, Hahn A, Agarwal AM, Gupta S, Albertson D, Alex A, Agarwal N (2016). Neutrophil-lymphocyte ratio (NLR) as a predictive biomarker for response to high dose interleukin 2 (HDIL-2) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr e 16087.
- Buckley TH, Alex A, Franham JM, Gill DM, Patel SB, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 222.
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill DM, Patel SB, Vaishampayan U, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 269.
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 610.
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 608.
- Gill DM, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 224.
- Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal A, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Clinical Cancer Research, 22(1 suppl), 39.
- Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi SR, Gastier-Foster JM, Schiffman JD, Miles RR (2015). Genomic analysis of adult B-ALL identifies changes in copy number profile at relapse and IKZF1/CDKN2A co-deletion at diagnosis as a marker of shorter survival [Abstract]. Blood, 126(23), 1427.
- Patel SB, Buckley TH, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone (T) and serum prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continuous androgen deprivation therapy (cADT) [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
- Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Schiffman JD, Miles RR (2015). IKZF1/CDKN2A Co-Deletion Predicts Shorter Survival in Adult B-ALL [Abstract]. Cancer Research, 75(15 suppl), 1723.
- Patel SB, Buckley TH, Gill D, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e16019.
- Patel SB, Stenehjem DD, Hsu J, Tantravahi SK, Gill D, Agarwal A, Batten JA, Agarwal N, Pal SK (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e15589.
- Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
- Reese ZL, Tometich D, Patel SB, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), abstr 311.
- Patel SB, Tometich D, Reese ZL, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), 687-687.
- Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Germline predictors of response to androgen deprivation therapy in men with advanced prostate cancer [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 162.
- Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 460.
- Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 495.
- Tantravahi SK, Patel SB, Ravulapati S, Batten J, Merriman J, Stenehjem DD, Agarwal N (2015). Long term response in metastatic renal cell carcinoma patients receiving first line therapy with vascular endothelial growth factor inhibitors with VEGF TKIs [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 436.
- Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms in ESR1 and PRMT8 and response to treatment with abiraterone acetate in men with metastatic castration refractory prostate cancer [Abstract]. Journal of Clinical Oncology, 33(suppl), abstr 5048.
- Patel SB, Gojo I, Tidwell M, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy [Abstract]. Journal of Clinical Oncology, 29(15 suppl), abstr 6579.
- Patel SB, Gojo I, Tidwell M, Ning Y, Zhao XF, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy [Abstract]. Journal of Clinical Onocology, 29(suppl), abstr 6579.
- Kerrigan K, Sinnott J, Haaland B, Puri S, Akerley W, Patel S (). Real World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy. Abstract submitted for 2021 World Conference on Lung Cancer (IASLC). September 8-14, 2021 [Abstract].
- Puri S, Naqash AR, Elliot A, Oliver T, Kerrigan K, Patel S, Seeber A, Kocher F, Uperty D, Mamdani H, Kulkarni A, Lopes G, Halmos B, Borghaei H, Akerley W, Liu S, Korn WM, Owonikoko T (). Real-world multi-omic characterization of small cell lung cancer subtypes reveals differential expression of clinically relevant biomarkers. Abstract accepted for 2021 ASCO Annual Meeting. [Abstract].